Skip to main content
SpringerLink
Log in

Liquid Gold

  • Chapter
  • First Online:
Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy

  • 523 Accesses

Abstract

Convalescent plasma has been used throughout history to manage pandemic outbreaks. Most recently, it has been used in the pandemic caused by the coronavirus disease 2019. Solve it!

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res. 2020;7(11):240. https://doi.org/10.1186/s40779-020-00240-0.

    Article  CAS  Google Scholar 

  2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. FDA new release. FDA expands authorization of two monoclonal antibodies for treatment and post-exposure prevention of COVID-19 to younger pediatric patients, including newborns. 2021. https://www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19. Accessed 9 Dec 2021.

  3. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14:152–7.

    PubMed  PubMed Central  Google Scholar 

  4. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Convalescent Plasma Study Group, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90.

    Article  CAS  PubMed  Google Scholar 

  5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry. Conduct of clinical trials of medical products during the COVID-19 public health emergency. 2020. Updated January 27, 2021. https://www.fda.gov/media/136238/download. Accessed 2 Feb 2021.

  6. FDA News Release. FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in Administration’s Fight Against Pandemic. 2020. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Accessed 2 Feb 2021.

  7. U.S. Department of Health and Human Services, Food and Drug Administration. Clinical memorandum. EUA 26382: Emergency Use Authorization (EUA) Request. 2020. https://www.fda.gov/media/141480/download. Accessed 4 Feb 2021.

  8. Ortho-Clinical Diagnostics, Inc. VITROS® immunodiagnostics products anti-SARS-CoV-2 IgG. Rochester: Ortho-Clinical Diagnostics, Inc.; 2020.

    Google Scholar 

  9. U.S. Food and Drug Administration. Revised letter of authorization. 2021. https://www.fda.gov/media/141477/download. Accessed 5 Feb 2021.

  10. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384:1015–27.

    Article  CAS  PubMed  Google Scholar 

  11. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:2049–59.

    Article  Google Scholar 

  12. World Health Organization. WHO recommends against the use of convalescent plasma to treat COVID-19. 2021. https://www.who.int/news/item/07-12-2021-who-recommends-against-the-use-of-convalescent-plasma-to-treat-covid-19. Accessed 9 Dec 2021.

  13. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes additional monoclonal antibody for treatment of COVID-19. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19. Accessed 25 Sept 2021.

  14. Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, For the CONTAIN COVID-19 Study Group, et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients. A randomized clinical trial. JAMA Intern Med. 2022;182(2):115–26.

    Article  CAS  PubMed  Google Scholar 

  15. Nguyen FT, van den Akker T, Lally K, Lam H, Lenskaya V, Liu STH, et al. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. Transfusion. 2021;61:78–93.

    Article  CAS  PubMed  Google Scholar 

  16. Khulood D, Adil MS, Sultana R, Nimra. Convalescent plasma appears efficacious and safe in COVID-19. Ther Adv Infect Dis. 2020;7:2049936120957931.

    CAS  PubMed  PubMed Central  Google Scholar 

Further Reading

  • Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res. 2020;7(11):1.

    CAS  Google Scholar 

  • Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, For the CONTAIN COVID-19 Study Group, et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients. A randomized clinical trial. JAMA Intern Med. 2022;182(2):115–26.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, NYU Lagone Health, Mineola, NY, USA

    Mark T. Friedman

  2. Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, MD, USA

    Kamille A. West

  3. Department of Pediatrics, Northwell Health System, Great Neck, NY, USA

    Peyman Bizargity

  4. Department of Pathology, Children’s Hospital Colorado, Aurora, CO, USA

    Kyle Annen

  5. Department of Pathology, Northwell Health System, Greenvale, NY, USA

    H. Deniz Gur

  6. Department of Pathology, NYU Langone Health, New York, NY, USA

    Timothy Hilbert

Authors
  1. Mark T. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kamille A. West
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peyman Bizargity
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kyle Annen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Deniz Gur
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Timothy Hilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark T. Friedman .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). Liquid Gold. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_92

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-14638-1_92

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-14637-4

  • Online ISBN: 978-3-031-14638-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation